We are live on
!
Find out more
RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$1.06B
1-Year Est. Return
52.03%
This Fund
S&P 500
This Quarter
Est. Return
+2.06%
1 Year Est. Return
+52.03%
3 Year Est. Return
+131.18%
5 Year Est. Return
+187.67%
10 Year Est. Return
+1,140.82%
AUM
$342M
AUM Growth
+$4.53M
(+1.3%)
Cap. Flow
-$12M
Cap. Flow
% of AUM
-3.51%
Top 10 Holdings %
Top 10 Hldgs %
27.24%
Holding
105
New
9
Increased
44
Reduced
37
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$8.51M |
| 2 |
Universal Health Services
UHS
|
+$7.3M |
| 3 |
AbbVie
ABBV
|
+$6.16M |
| 4 |
RAD
Rite Aid Corporation
RAD
|
+$5.54M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$4.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$10.6M |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$8.41M |
| 3 |
CELG
Celgene Corp
CELG
|
+$6.93M |
| 4 |
Biogen
BIIB
|
+$6.92M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$5.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.61% |
| 2 | Miscellaneous | 16.01% |
| 3 | Financials | 1.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Johnson & Johnson
JNJ
$646B
| $14.9M | 4.37% |
+140,000
| New | +$14.5M |
|
2
Alkermes
ALKS
$7.83B
| $11.4M | 3.34% |
266,000
+98,000
| +58% | +$4.39M |
|
|
3
Universal Health Services
UHS
$10.7B
| $10.3M | 3.02% |
98,700
+68,700
| +229% | +$7.3M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
| $9.62M | 2.82% |
58,000
-35,000
| -38% | -$5.75M |
|
|
5
Biogen
BIIB
$32.1B
| $9.59M | 2.81% |
29,000
-21,000
| -42% | -$6.92M |
|
|
SLXP
6
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $8.44M | 2.47% |
54,000
+10,507
| +24% | +$1.52M |
|
|
7
Gilead Sciences
GILD
$185B
| $7.66M | 2.24% |
72,000
-108,000
| -60% | -$10.6M |
|
|
CELG
8
DELISTED
Celgene Corp
CELG
| $7.58M | 2.22% |
80,000
-76,781
| -49% | -$6.93M |
|
|
9
Medtronic
MDT
$119B
| $6.87M | 2.01% |
+133,800
| New | +$8.51M |
|
10
BioMarin Pharmaceuticals
BMRN
$12.7B
| $6.64M | 1.94% |
92,000
-58,000
| -39% | -$3.81M |
|
|
COV
11
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
| $6.58M | 1.93% |
76,000
-95,000
| -56% | -$8.41M |
|
|
12
AbbVie
ABBV
$463B
| $6.41M | 1.88% |
+111,000
| New | +$6.16M |
|
13
Nektar Therapeutics
NKTR
$2.37B
| $6.13M | 1.8% |
33,867
+16,534
| +95% | +$3.16M |
|
14
Thermo Fisher Scientific
TMO
$242B
| $5.96M | 1.75% |
49,000
+16,000
| +48% | +$1.95M |
|
|
NPSP
15
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $5.82M | 1.71% |
224,000
+157,000
| +234% | +$4.51M |
|
16
CVS Health
CVS
$117B
| $5.73M | 1.68% |
72,000
+22,000
| +44% | +$1.73M |
|
17
Acadia Pharmaceuticals
ACAD
$4.73B
| $5.42M | 1.59% |
219,000
-11,000
| -5% | -$257K |
|
|
RAD
18
DELISTED
Rite Aid Corporation
RAD
| $5.41M | 1.58% |
55,900
+42,900
| +330% | +$5.54M |
|
19
Incyte
INCY
$25.5B
| $5.25M | 1.54% |
107,000
-26,000
| -20% | -$1.3M |
|
20
Bristol-Myers Squibb
BMY
$129B
| $5.07M | 1.48% |
99,000
+14,000
| +16% | +$699K |
|
21
Vertex Pharmaceuticals
VRTX
$130B
| $4.83M | 1.41% |
43,000
-58,600
| -58% | -$5.58M |
|
|
AGN
22
DELISTED
Allergan plc
AGN
| $4.83M | 1.41% |
20,000
-5,000
| -20% | -$1.12M |
|
23
Regeneron Pharmaceuticals
REGN
$80.4B
| $4.6M | 1.35% |
13,000
-9,500
| -42% | -$3.18M |
|
|
PCYC
24
DELISTED
PHARMACYCLICS INC
PCYC
| $4.46M | 1.31% |
38,000
-17,000
| -31% | -$1.94M |
|
25
Cardinal Health
CAH
$53B
| $4.42M | 1.29% |
59,000
-40,000
| -40% | -$2.91M |
|
Similar funds
JSC
PCI
SAM
PCM
BDP
GX
CIC
RCIM
Rhenman & Partners Asset Management's Q3 2014 Portfolio in Review
As of Q3 2014, Rhenman & Partners Asset Management held 105 positions worth $342M, up 1.3% from $337M the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Rhenman & Partners Asset Management withdrew a net $12M in Q3 2014, closing 6 positions and reducing 37 holdings. Its most notable exit was Myriad Genetics, an estimated $3.11M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Rhenman & Partners Asset Management opened a new position in Medtronic worth $6.87M.
- Rhenman & Partners Asset Management's largest Q3 2014 buy was Medtronic: 133,800 shares worth $6.87M.
- Rhenman & Partners Asset Management added most to Universal Health Services in Q3 2014, an estimated $7.3M increase.
- Rhenman & Partners Asset Management's biggest Q3 2014 reduction was Gilead Sciences, cutting an estimated $10.6M.
- Rhenman & Partners Asset Management fully exited Myriad Genetics in Q3 2014, selling an estimated $3.11M.
- Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $342M portfolio in Q3 2014.
- Rhenman & Partners Asset Management opened 9 new positions and closed 6 in Q3 2014.
- Rhenman & Partners Asset Management's portfolio value rose 1.3% quarter-over-quarter to $342M.
Based on Rhenman & Partners Asset Management's 13F filing for Q3 2014, filed 3 Nov 2014.